Plasma MMP1, MMP8 and MMP13 expression in breast cancer: protective role of MMP8 against lymph node metastasis

Por Decock, J, Hendrickx, W, Vanleeuw, U, Christiaens, MR, Ye, S, Paridaens, R
Publicado em 2008

Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas

Por Decock, J., Hendrickx, W., Drijkoningen, M., Wildiers, H., Neven, P., Smeets, A., Paridaens, R.
Publicado em 2007

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

Por Huang, H J, Neven, P, Drijkoningen, M, Paridaens, R, Wildiers, H, Van Limbergen, E, Berteloot, P, Amant, F, Vergote, I, Christiaens, M R
Publicado em 2005

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

Por Hanauske, A. R., Catimel, G., Aamdal, S., ten Bokkel Huinink, W., Paridaens, R., Pavlidis, N., Kaye, S. B., te Velde, A., Wanders, J., Verweij, J.
Publicado em 1996

Short-Term Prognostic Index for Breast Cancer: NPI or Lpi

Por Van Belle, V., Decock, J., Hendrickx, W., Brouckaert, O., Pintens, S., Moerman, P., Wildiers, H., Paridaens, R., Christiaens, M. R., Van Huffel, S., Neven, P.
Publicado em 2010

Association of MMP8 gene variation with breast cancer prognosis

Por Decock, J, Long, JR, Laxton, RC, Shu, XO, Hodgkinson, C, Hendrickx, W, Pearce, EG, Gao, YT, Pereira, AC, Paridaens, R, Zheng, W, Ye, S
Publicado em 2008

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.

Por Bontenbal, M., Andersson, M., Wildiers, J., Cocconi, G., Jassem, J., Paridaens, R., Rotmensz, N., Sylvester, R., Mouridsen, H. T., Klijn, J. G., van Oosterom, A. T.
Publicado em 1998

Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

Por Beuselinck, B, Wolter, P, Karadimou, A, Elaidi, R, Dumez, H, Rogiers, A, Van Cann, T, Willems, L, Body, J-J, Berkers, J, Van Poppel, H, Lerut, E, Debruyne, P, Paridaens, R, Schöffski, P
Publicado em 2012

A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours

Por Paridaens, R, Uges, D R A, Barbet, N, Choi, L, Seeghers, M, Graaf, W T A van der, Groen, H J M, Dumez, H, Buuren, I Van, Muskiet, F, Capdeville, R, Oosterom, A T van, Vries, E G E de
Publicado em 2000

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

Por Rabaglio, M., Sun, Z., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J., Colleoni, M., Pienkowski, T., Nogaret, J.-M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S.
Publicado em 2009

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

Por Beuselinck, B, Karadimou, A, Lambrechts, D, Claes, B, Wolter, P, Couchy, G, Berkers, J, Paridaens, R, Schöffski, P, Méjean, A, Verkarre, V, Lerut, E, de la Taille, A, Tourani, J-M, Bigot, P, Linassier, C, Négrier, S, Berger, J, Patard, J-J, Zucman-Rossi, J, Oudard, S
Publicado em 2013

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

Por Viale, G., Regan, M. M., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M., Láng, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S.
Publicado em 2011